NewsRoom

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

20122011201020092008

Aug 29, 2019
MEI Pharma to Present at the 2019 Wells Fargo Healthcare Conference
Aug 28, 2019
MEI Pharma Reports Fiscal Year 2019 Results and Operational Highlights
- Clinical Progress Continues Across Oncology Portfolio, Highlighted by Expanding ME-401 Data Set Supporting Expedited Development Strategies and Additional Combination Therapy Opportunities -
Aug 21, 2019
MEI Pharma to Release 2019 Fiscal Year End Financial Results and Provide Corporate Update on August 28, 2019
Jul 3, 2019
MEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors
Jun 21, 2019
MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)
Jun 3, 2019
MEI Pharma Presents Updated Clinical Data from the ME-401 Monotherapy and in Combination with Rituximab Phase 1b study in Patients with Follicular Lymphoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 1, 2019
MEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
- Statistically significant biologic anti-tumor activity demonstrated as measured by a reduction in Ki67 in patients treated with ME-344 compared to an increase in patients receiving placebo -
May 31, 2019
MEI Pharma to Present at the Jefferies 2019 Global Healthcare Conference
May 15, 2019
MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
International Conference on Malignant Lymphoma (ICML) Selects ME-401 Abstract for Oral Presentation
May 9, 2019
MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights
Apr 2, 2019
MEI Pharma to Present at the 18th Annual Needham Healthcare Conference
Mar 12, 2019
MEI Pharma to Present at the 29th Annual Oppenheimer Healthcare Conference
Feb 14, 2019
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advance
Feb 7, 2019
MEI Pharma Reports Second Quarter Fiscal Year 2019 Results and Operational Highlights
-- MEI Remains in Strong Position as ME-401 Advances to Global Phase 2 Study to Support FDA Accelerated Approval --
Dec 3, 2018
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting